PE20241477A1 - Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii - Google Patents
Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-briiInfo
- Publication number
- PE20241477A1 PE20241477A1 PE2024001077A PE2024001077A PE20241477A1 PE 20241477 A1 PE20241477 A1 PE 20241477A1 PE 2024001077 A PE2024001077 A PE 2024001077A PE 2024001077 A PE2024001077 A PE 2024001077A PE 20241477 A1 PE20241477 A1 PE 20241477A1
- Authority
- PE
- Peru
- Prior art keywords
- tgf
- binding
- multispecific
- brii
- binding domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2029844 | 2021-11-19 | ||
| PCT/EP2022/082377 WO2023089083A1 (en) | 2021-11-19 | 2022-11-18 | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241477A1 true PE20241477A1 (es) | 2024-07-17 |
Family
ID=80625531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001077A PE20241477A1 (es) | 2021-11-19 | 2022-11-18 | Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230159645A1 (https=) |
| EP (1) | EP4433505A1 (https=) |
| JP (1) | JP2024542879A (https=) |
| KR (1) | KR20240101664A9 (https=) |
| CN (2) | CN118265725A (https=) |
| AR (1) | AR127714A1 (https=) |
| AU (1) | AU2022389596A1 (https=) |
| CA (1) | CA3231649A1 (https=) |
| CL (1) | CL2024001410A1 (https=) |
| CO (1) | CO2024006325A2 (https=) |
| CR (1) | CR20240201A (https=) |
| EC (1) | ECSP24039278A (https=) |
| IL (1) | IL312214A (https=) |
| MX (1) | MX2024006018A (https=) |
| PE (1) | PE20241477A1 (https=) |
| TW (1) | TW202328180A (https=) |
| UY (1) | UY40028A (https=) |
| WO (1) | WO2023089083A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240343805A1 (en) * | 2023-04-14 | 2024-10-17 | Incyte Corporation | USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| MX2020000055A (es) * | 2017-07-06 | 2020-08-06 | Merus Nv | Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3). |
| AU2018296067B2 (en) * | 2017-07-06 | 2021-06-10 | Merus B.V. | Binding molecules that modulate a biological activity expressed by a cell |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
-
2022
- 2022-11-18 PE PE2024001077A patent/PE20241477A1/es unknown
- 2022-11-18 CA CA3231649A patent/CA3231649A1/en active Pending
- 2022-11-18 EP EP22818694.6A patent/EP4433505A1/en active Pending
- 2022-11-18 MX MX2024006018A patent/MX2024006018A/es unknown
- 2022-11-18 CN CN202280076849.XA patent/CN118265725A/zh active Pending
- 2022-11-18 WO PCT/EP2022/082377 patent/WO2023089083A1/en not_active Ceased
- 2022-11-18 CR CR20240201A patent/CR20240201A/es unknown
- 2022-11-18 JP JP2024524389A patent/JP2024542879A/ja active Pending
- 2022-11-18 IL IL312214A patent/IL312214A/en unknown
- 2022-11-18 KR KR1020247019354A patent/KR20240101664A9/ko active Pending
- 2022-11-18 AR ARP220103179A patent/AR127714A1/es unknown
- 2022-11-18 CN CN202411831660.4A patent/CN119613560A/zh active Pending
- 2022-11-18 US US18/056,907 patent/US20230159645A1/en active Pending
- 2022-11-18 UY UY0001040028A patent/UY40028A/es unknown
- 2022-11-18 TW TW111144080A patent/TW202328180A/zh unknown
- 2022-11-18 AU AU2022389596A patent/AU2022389596A1/en active Pending
-
2024
- 2024-05-10 CL CL2024001410A patent/CL2024001410A1/es unknown
- 2024-05-17 CO CONC2024/0006325A patent/CO2024006325A2/es unknown
- 2024-05-21 EC ECSENADI202439278A patent/ECSP24039278A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024006325A2 (es) | 2024-06-27 |
| CL2024001410A1 (es) | 2024-08-30 |
| US20230159645A1 (en) | 2023-05-25 |
| WO2023089083A1 (en) | 2023-05-25 |
| UY40028A (es) | 2023-05-31 |
| AU2022389596A1 (en) | 2024-05-30 |
| CN118265725A (zh) | 2024-06-28 |
| ECSP24039278A (es) | 2024-07-31 |
| KR20240101664A (ko) | 2024-07-02 |
| JP2024542879A (ja) | 2024-11-18 |
| MX2024006018A (es) | 2024-07-29 |
| EP4433505A1 (en) | 2024-09-25 |
| AR127714A1 (es) | 2024-02-21 |
| IL312214A (en) | 2024-06-01 |
| CN119613560A (zh) | 2025-03-14 |
| TW202328180A (zh) | 2023-07-16 |
| CR20240201A (es) | 2024-07-15 |
| CA3231649A1 (en) | 2023-05-25 |
| KR20240101664A9 (ko) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003788A1 (es) | Moléculas de unión contra bcma y usos de las mismas | |
| CL2020003392A1 (es) | Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172) | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| GT201500248A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| GT201400066A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
| MX375222B (es) | Compuestos y su uso para reducir los niveles de ácido úrico | |
| MX2021012813A (es) | Conjugados de citocina de liberacion lenta. | |
| CO2018000414A2 (es) | Inmunoconjugados de il22 | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| BR112021018205A2 (pt) | Pequenos agentes bloqueadores de liberação. | |
| CO2021014748A2 (es) | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo | |
| PE20241477A1 (es) | Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii | |
| MX2018011170A (es) | Metodos y composiciones para incrementar la produccion de arn bicatenario. | |
| DOP2023000207A (es) | Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 novedosos | |
| CL2009000177A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas; linea celular de hibridoma que lo produce; composicion farmaceutica que los comprende; ensayo para determinar la presencia de celulas cancerosas; y uso para tratar tumores. |